These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 29058279)
21. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP; Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP; Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698 [TBL] [Abstract][Full Text] [Related]
23. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. Barbieri L; Verdoia M; Pergolini P; Nardin M; Rolla R; Marino P; Bellomo G; Suryapranata H; De Luca G; Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):352-8. PubMed ID: 26857781 [TBL] [Abstract][Full Text] [Related]
24. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Wouter Jukema J; Collet JP; De Luca L Curr Med Res Opin; 2012 Feb; 28(2):203-11. PubMed ID: 22181345 [TBL] [Abstract][Full Text] [Related]
25. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L; Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. Xin YG; Zhang HS; Li YZ; Guan QG; Guo L; Gao Y; Yu HJ; Zhang XG; Xu F; Zhang YL; Jia DL; Sun YX; Qi GX; Tian W Int J Cardiol; 2017 Feb; 228():275-279. PubMed ID: 27865197 [TBL] [Abstract][Full Text] [Related]
27. High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis. Lin L; Wang H; Chen YF; Lin WW; Wang CL; Lin CH Coron Artery Dis; 2015 Aug; 26(5):386-95. PubMed ID: 25886999 [TBL] [Abstract][Full Text] [Related]
34. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282 [TBL] [Abstract][Full Text] [Related]
35. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Lewis BS; Murphy SA; McCabe CH; Braunwald E; JAMA; 2005 Sep; 294(10):1224-32. PubMed ID: 16143698 [TBL] [Abstract][Full Text] [Related]
36. Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). Mangiacapra F; Panaioli E; Colaiori I; Ricottini E; Lauria Pantano A; Pozzilli P; Barbato E; Di Sciascio G Circulation; 2016 Sep; 134(11):835-7. PubMed ID: 27619717 [No Abstract] [Full Text] [Related]
37. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678 [TBL] [Abstract][Full Text] [Related]
38. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G; Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440 [TBL] [Abstract][Full Text] [Related]
39. Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention. Yudi MB; Eccleston D; Andrianopoulos N; Farouque O; Duffy SJ; Brennan A; Reid C; Clark DJ; Ajani AE; Intern Med J; 2015 Oct; 45(10):1032-7. PubMed ID: 26013065 [TBL] [Abstract][Full Text] [Related]
40. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis. Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW; JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]